Glaucoma Eye Articles & Analysis: Older
18 news found
To help pharmaceutical partners and academic institutions overcome the challenges of low bioavailability and unsustainable drug release in drug formations for glaucoma, Ace Therapeutics is proud to announce the unveiling of its cutting-edge drug delivery system development services for the treatment of glaucoma. Glaucoma is a serious ...
SAN DIEGO–(BUSINESS WIRE)–Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces the acceptance and presentation of a poster highlighting its latest clinical results at the upcoming Global Specialty Lens Symposium (GSLS), a leading eye care conference. ...
Recent Business Highlights Generated first quarter 2022 total revenue of $14.9 million, an increase of 72% compared to the prior year period Increased the number of facilities ordering the OMNI® Surgical System from 760 in the fourth quarter of 2021 to 811 in the first quarter of 2022, and the installed base of TearCare® facilities from 562 on December 31, 2021 to 635 on March 31, ...
Recent Business Highlights Generated 2021 total revenue of $49.0 million, an increase of 77% compared to the prior year Generated fourth quarter 2021 total revenue of $14.7 million, an increase of 63% compared to the prior year period Expanded total gross margin to 87% in the fourth quarter 2021 versus 74% in the prior year period Received FDA 510(k) Clearance of the TearCare® System ...
I look forward to contributing toward its next stages of growth as they expand their existing businesses in glaucoma and dry eye and develop their robust pipeline of innovations in ophthalmology and ...
Melbourne, Australia – March 4, 2022 – PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular implants with sustained drug delivery for patients suffering from ophthalmic diseases such as glaucoma, today announced that data from the Phase IIa study of its PA5108 Ocular Implant for the treatment of ...
IOP-Connect is based on an implantable intra-ocular pressure (IOP) sensor platform smaller than a grain of rice, that for the first time is expected to provide continuous and autonomous long-term IOP data from inside a glaucoma patient’s eye. The funding follows IOP-Connect’s FDA Breakthrough Device Program (BDP) designation in 2020 and covers 2 ...
Melbourne, Australia – February 17, 2022 – PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular implants with sustained drug delivery for patients suffering from ophthalmic diseases such as glaucoma, today announced that the Phase IIa study of its PA5108 Ocular Implant for the treatment of Primary ...
Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces its new corporate branding and new website. ...
This data aligns with prior secondary, independent patient research from Johns Hopkins University showing that 56% – 59% of glaucoma patients would accept contact lens to treat their disease if they made glaucoma surgery unnecessary or were more effective than eye drops. ...
Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces the successful completion of the first study in its SIGHT (Sustained Innovative Glaucoma and ocular Hypertension Treatment) clinical program aimed at treating mild to moderate glaucoma and ...
The Latanoprost FA SR Ocular Implant is designed to substitute for daily drop therapy by providing sustained treatment from a single implant administration over a six-month period to treat glaucoma. Up to 46 percent of patients do not remember to use their eye drops or administer them poorly. Adherence to daily drop therapy is critical to slow progression of ...
Leo Lens expanded its SAB with four eye care practitioners who are highly experienced in the glaucoma field as the company prepares for its first human clinical trial with its lead asset to treat glaucoma and ocular hypertension. ...
LL-BMT1 is a therapeutic contact lens that delivers preservative-free bimatoprost to the eye to treat glaucoma for one week. After a productive Pre-IND meeting with the FDA, Leo Lens has now successfully completed GLP biocompatibility studies required by the FDA, secured a clinical research organization to oversee the initial human clinical trial, secured the ...
Ivantis, Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients, announced today the first-ever, four-year follow-up data for a MIGS device in an FDA pivotal trial. ...
It comprises nearly 3,000 eyes and to date has over 70% follow-up. Of the procedures captured in the SPECTRUM Registry, over 700 were in stand-alone glaucoma cases — the largest reported series of stand-alone glaucoma cases in MIGS. ...
Current glaucoma treatment requires eye drops to be administered daily, often multiple times each day. ...
In this study, LayerBio's proprietary intracameral extended-release formulation of the glaucoma drug travoprost is shown to lower intraocular pressure to therapeutic levels for longer than six months. "Implantable extended release formulations are an emerging class of treatments for glaucoma. Conventional eye drops are often ineffective due to ...